Literature DB >> 31830749

Prevalence of and Risk Factors for Cerebral Microbleeds in Moyamoya Disease and Syndrome in the American Population.

Nadeem I Khan1, Ali A Saherwala1, Mo Chen1, Sepand Salehian2, Hisham Salahuddin1, Babu G Welch3,2, Marco C Pinho2, Ty Shang4.   

Abstract

BACKGROUND AND
PURPOSE: Cerebral microbleeds (CMB) are reported to be frequent in moyamoya disease (MMD) and moyamoya syndrome (MMS) in the Asian population. It is associated with an increased risk of intracerebral hemorrhage. The significance of CMB in MMD/MMS in non-Asian populations has not been well established. Our study aimed to investigate the prevalence of CMB in MMD/MMS in a moymoya cohort with a majority of non-Asians and to identify risk factors for developing a CMB and its predictive value for subsequent vascular events.
METHODS: The moyamoya database was compiled by screening for MMD/MMS among patients admitted to the Zale-Lipshy University Hospital at the University of Texas Southwestern Medical Center. We identified and analyzed data of 67 patients with MMD or MMS. Patients were characterized as CMB+ or CMB- based on MRI findings. In CMB+ patients, the total number and location of CMB were identified. Univariate and multivariate logistic regression were used to identify risk factors for developing CMB and whether CMB are associated with the development of subsequent vascular events.
RESULTS: Out of a total of 67 patients, 11 (16%) had CMB. Males had significantly higher odds of having CMB as compared to females (OR 1.76; 95% CI 1.40-24.3, p = 0.021). The incidence of CMB was also associated with age at diagnosis (mean age of CMB+ patients vs. CMB- patients: 44 vs. 34 years, respectively, p = 0.024), smoking (p = 0.006), and hemorrhagic stroke at presentation (p = 0.034). Logistic regression with multivariate analysis found that gender and age at diagnosis remained statistically significant. New ischemic events occurred in 2 (20%) out of 10 CMB+ patients and 13 (23%) out of 55 CMB- patients, respectively (p = 0.79). While 2 (3%) CMB- patients had a new cerebral hemorrhage during follow-up, none of the CMB+ patients did.
CONCLUSIONS: CMB are less prevalent in MMD/MMS in the USA than in Asia. An older age at diagnosis and male gender were associated with CMB. The presence of CMB was not associated with an increased risk of a subsequent ischemic or hemorrhagic stroke.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Cerebral microbleeds; Moyamoya syndrome; Population studies; Stroke

Mesh:

Year:  2019        PMID: 31830749      PMCID: PMC6940455          DOI: 10.1159/000504530

Source DB:  PubMed          Journal:  Cerebrovasc Dis Extra        ISSN: 1664-5456


  30 in total

1.  Microbleeds in moyamoya disease: susceptibility-weighted imaging versus T2*-weighted imaging at 3 Tesla.

Authors:  Nobuyuki Mori; Yukio Miki; Ken-ichiro Kikuta; Yasutaka Fushimi; Tsutomu Okada; Shin-ichi Urayama; Nobukatsu Sawamoto; Hidenao Fukuyama; Nobuo Hashimoto; Kaori Togashi
Journal:  Invest Radiol       Date:  2008-08       Impact factor: 6.016

2.  Clinical features and outcome in North American adults with moyamoya phenomenon.

Authors:  Christopher L Hallemeier; Keith M Rich; Robert L Grubb; Michael R Chicoine; Christopher J Moran; DeWitte T Cross; Gregory J Zipfel; Ralph G Dacey; Colin P Derdeyn
Journal:  Stroke       Date:  2006-04-27       Impact factor: 7.914

3.  Tuberous sclerosis with moyamoya disease. Case report.

Authors:  M Imaizumi; T Nukada; S Yoneda; T Takano; K Hasegawa; H Abe
Journal:  Med J Osaka Univ       Date:  1978-03

4.  Prevalence of asymptomatic microbleeds in patients with moyamoya disease.

Authors:  Tatsuya Ishikawa; Satoshi Kuroda; Naoki Nakayama; Satoshi Terae; Kousuke Kudou; Yoshinobu Iwasaki
Journal:  Neurol Med Chir (Tokyo)       Date:  2005-10       Impact factor: 1.742

5.  Risk Factors Associated With Incident Cerebral Microbleeds According to Location in Older People: The Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study.

Authors:  Jie Ding; Sigurdur Sigurdsson; Melissa Garcia; Caroline L Phillips; Gudny Eiriksdottir; Vilmundur Gudnason; Mark A van Buchem; Lenore J Launer
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

6.  Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events.

Authors:  Scott R Dobson; Kenton R Holden; Paul J Nietert; Joel K Cure; Joseph H Laver; Deborah Disco; Miguel R Abboud
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 7.  Moyamoya disease and Down syndrome: case report and review of the literature.

Authors:  Valérie de Borchgrave; Françoise Saussu; Anne Depre; Thierry de Barsy
Journal:  Acta Neurol Belg       Date:  2002-06       Impact factor: 2.396

8.  Incidence, locations, and longitudinal course of silent microbleeds in moyamoya disease: a prospective T2*-weighted MRI study.

Authors:  Satoshi Kuroda; Daina Kashiwazaki; Tatsuya Ishikawa; Naoki Nakayama; Kiyohiro Houkin
Journal:  Stroke       Date:  2012-12-06       Impact factor: 7.914

9.  Stroke in Children with Sickle Cell Disease.

Authors:  Fenella J. Kirkham; Michael R. DeBaun
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

10.  Novel epidemiological features of moyamoya disease.

Authors:  T Baba; K Houkin; S Kuroda
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12-12       Impact factor: 10.154

View more
  2 in total

1.  Association of intracranial vessel wall enhancement and cerebral hemorrhage in moyamoya disease: a high-resolution magnetic resonance imaging study.

Authors:  Mingming Lu; Hongtao Zhang; Cong Han; Jianming Cai; Dongqing Liu; Xu Liu; Lichen Zhang; Peng Peng; Fei Yuan; Shitong Liu; Fugeng Sheng; Yuan Liu; Yao He; Xihai Zhao; Qian Zhang; Heguan Fu
Journal:  J Neurol       Date:  2021-05-06       Impact factor: 4.849

2.  Surgical revascularization vs. conservative treatment for adult hemorrhagic moyamoya disease: analysis of rebleeding in 322 consecutive patients.

Authors:  Shaojie Yu; Nan Zhang; Jian Liu; Changwen Li; Sheng Qian; Yong Xu; Tao Yang; Nan Li; Minghui Zeng; Dongxue Li; Chengyu Xia
Journal:  Neurosurg Rev       Date:  2021-12-03       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.